The EGFR is considered one of the important protein targets in the development of anticancer drugs and therefore, the inhibition of EGFR is essential for the treatment of cancer to inhibit the progression and growth of EGFR-expressing tumor cells [2]. This evidence concerns the gene EGFR and neoplasm.